BioCentury | Jan 21, 2013
Company News

Alzheimer's Disease Cooperative Study (ADCS), NIH neurology news

NIH's National Institute on Aging awarded $11 million for FY13 to the ADCS consortium to support four clinical trials evaluating potential Alzheimer's disease treatments. The consortium said it is eligible to receive up to $55...
BioCentury | Jan 15, 2013
Politics & Policy

Alzheimer's consortium to conduct NIH-supported studies

NIH's National Institute on Aging awarded $11 million for FY13 to the Alzheimer's Disease Cooperative Study (ADCS) consortium to support four clinical trials evaluating potential Alzheimer's disease treatments. The consortium said it is eligible to...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...4(40); doi:10.1038/scibx.2011.1115 Published online Oct. 13, 2011 Patent application filed; licensing negotiations are ongoing with Clear Therapeutics Inc....
BioCentury | May 26, 2011
Strategy

iPS cells: Five years later

Despite the proliferation of technologies to derive induced pluripotent stem cells since they were first described five years ago, this has been a technology in search of a home. The tide may have finally turned....
BioCentury | Mar 4, 2010
Targets & Mechanisms

Casting a lure for EGFR ligands

Researchers at The University of Texas M.D. Anderson Cancer Center have identified an EGFR-mimicking peptide that lures ligands away from the receptor, thus preventing its activation and halting tumor growth. 1 Although toxicity and pharmacokinetic...
BioCentury | Jan 18, 2010
Product Development

Expanding the ICAM-1 space

Candidates targeting intercellular adhesion molecule-1 for inflammatory disease have been in development for more than a decade. Now BioInvent International AB is building a case for the role of ICAM-1 in multiple myeloma. The biotech...
BioCentury | Jul 9, 2009
Cover Story

Anexon's fail-safe BNP

Researchers at the Mayo Clinic and University of Minnesota have identified an alternatively spliced form of the hormone B-type natriuretic peptide that lacks the blood pressure-lowering effects that have curtailed the use of its regular...
BioCentury | Sep 19, 2005
Product Development

New hypothesis = new trials

Members of FDA's Oncologic Drugs Advisory Committee had a message last week for companies whose trials don't show clear results: it's fine to do data-dredging, but finding a subset of patients who might respond to...
BioCentury | Aug 30, 1999
Tools & Techniques

Don't hold your breath

Since developing treatments even for specific aging-related diseases such as Alzheimer's disease is proving difficult, it seems reasonable to assume that industry may have a tough time gaining a foothold on the aging process itself....
Items per page:
1 - 9 of 9
BioCentury | Jan 21, 2013
Company News

Alzheimer's Disease Cooperative Study (ADCS), NIH neurology news

NIH's National Institute on Aging awarded $11 million for FY13 to the ADCS consortium to support four clinical trials evaluating potential Alzheimer's disease treatments. The consortium said it is eligible to receive up to $55...
BioCentury | Jan 15, 2013
Politics & Policy

Alzheimer's consortium to conduct NIH-supported studies

NIH's National Institute on Aging awarded $11 million for FY13 to the Alzheimer's Disease Cooperative Study (ADCS) consortium to support four clinical trials evaluating potential Alzheimer's disease treatments. The consortium said it is eligible to...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...4(40); doi:10.1038/scibx.2011.1115 Published online Oct. 13, 2011 Patent application filed; licensing negotiations are ongoing with Clear Therapeutics Inc....
BioCentury | May 26, 2011
Strategy

iPS cells: Five years later

Despite the proliferation of technologies to derive induced pluripotent stem cells since they were first described five years ago, this has been a technology in search of a home. The tide may have finally turned....
BioCentury | Mar 4, 2010
Targets & Mechanisms

Casting a lure for EGFR ligands

Researchers at The University of Texas M.D. Anderson Cancer Center have identified an EGFR-mimicking peptide that lures ligands away from the receptor, thus preventing its activation and halting tumor growth. 1 Although toxicity and pharmacokinetic...
BioCentury | Jan 18, 2010
Product Development

Expanding the ICAM-1 space

Candidates targeting intercellular adhesion molecule-1 for inflammatory disease have been in development for more than a decade. Now BioInvent International AB is building a case for the role of ICAM-1 in multiple myeloma. The biotech...
BioCentury | Jul 9, 2009
Cover Story

Anexon's fail-safe BNP

Researchers at the Mayo Clinic and University of Minnesota have identified an alternatively spliced form of the hormone B-type natriuretic peptide that lacks the blood pressure-lowering effects that have curtailed the use of its regular...
BioCentury | Sep 19, 2005
Product Development

New hypothesis = new trials

Members of FDA's Oncologic Drugs Advisory Committee had a message last week for companies whose trials don't show clear results: it's fine to do data-dredging, but finding a subset of patients who might respond to...
BioCentury | Aug 30, 1999
Tools & Techniques

Don't hold your breath

Since developing treatments even for specific aging-related diseases such as Alzheimer's disease is proving difficult, it seems reasonable to assume that industry may have a tough time gaining a foothold on the aging process itself....
Items per page:
1 - 9 of 9